{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:04:45Z","timestamp":1791986685543,"version":"4.4.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00679","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:18:05Z","timestamp":1554250685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":102,"title":["Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases"],"prefix":"10.3389","volume":"10","author":[{"given":"Fabienne","family":"Coury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Peyruchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Machuca-Gayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.177.4051.793","article-title":"Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes","volume":"177","author":"Horton","year":"1972","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/35046196","article-title":"Bone versus immune system","volume":"408","author":"Arron","year":"2000","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","article-title":"Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies","volume":"73","author":"Kleyer","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780330303","article-title":"Use of the radiograph to measure the course of rheumatoid arthritis. The gold standard versus fool's gold","volume":"33","author":"Brower","year":"1990","journal-title":"Arthritis Rheum"},{"key":"B8","first-page":"891","article-title":"Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry","volume-title":"Rheumatology.","author":"Szentpetery","year":"2016"},{"key":"B9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","article-title":"Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register","volume":"43","author":"Haugeberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10067-010-1538-8","article-title":"Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies","volume":"30","author":"van der Weijden","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-011-1766-z","article-title":"High frequency of vertebral fractures in early spondylarthropathies","volume":"23","author":"van der Weijden","year":"2012","journal-title":"Osteoporos Int"},{"key":"B12","first-page":"234","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention","volume-title":"Nat Rev Drug Discov.","author":"Redlich","year":"2012"},{"key":"B13","first-page":"224","article-title":"Inflammatory rheumatic disorders and bone","volume-title":"Curr Rheumatol Rep.","author":"Bultink","year":"2012"},{"key":"B14","first-page":"122","article-title":"IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation","volume-title":"J Clin Invest.","author":"Gao","year":"2007"},{"key":"B15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/ard.62.4.347","article-title":"Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha","volume":"62","author":"Allali","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1152\/physrev.00011.2015","article-title":"Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy","volume":"96","author":"Hartmann","year":"2016","journal-title":"Physiol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.berh.2016.08.010","article-title":"Imaging in osteoporosis in rheumatic diseases","volume":"30","author":"Mandl","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0149-2918(04)90001-X","article-title":"Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis","volume":"26","author":"Boling","year":"2004","journal-title":"Clin Ther"},{"key":"B20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/art.1780270902","article-title":"Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint","volume":"27","author":"Bromley","year":"1984","journal-title":"Arthritis Rheum"},{"key":"B21","first-page":"943","article-title":"Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis","volume":"152","author":"Gravallese","year":"1998","journal-title":"Am J Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","article-title":"Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis","volume":"161","author":"Romas","year":"2002","journal-title":"Am J Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","article-title":"TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis","volume":"159","author":"Pettit","year":"2001","journal-title":"Am J Pathol"},{"key":"B26","first-page":"1419","article-title":"Osteoclasts are essential for TNF-alpha-mediated joint destruction","volume-title":"J Clin Invest.","author":"Redlich","year":"2002"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1073\/pnas.0401602101","article-title":"The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase","volume":"101","author":"Mocsai","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature02444","article-title":"Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis","volume":"428","author":"Koga","year":"2004","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/ard.61.12.1047","article-title":"Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis","volume":"61","author":"Crotti","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1172\/JCI16069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J Clin Invest"},{"key":"B31","first-page":"123","article-title":"Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls","volume-title":"Rheumatology.","author":"Haynes","year":"2003"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/ard.2009.121764","article-title":"Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis","volume":"69","author":"van Tuyl","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.23818","article-title":"Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome","volume":"59","author":"Haynes","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/art.21824","article-title":"Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis","volume":"54","author":"Jarrett","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/art.20384","article-title":"Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis","volume":"50","author":"Herrak","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.20382","article-title":"Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis","volume":"50","author":"Sims","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B37","first-page":"569","article-title":"Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients","volume-title":"Arthritis Care Res.","author":"Deodhar","year":"2010"},{"key":"B38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/ard.2006.057497","article-title":"Radiological damage in patients with rheumatoid arthritis on sustained remission","volume":"66","author":"Cohen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/annrheumdis-2014-207137","article-title":"RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation","volume":"75","author":"Danks","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2","article-title":"Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients","volume":"44","author":"Kotake","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1002\/art.10607","article-title":"Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis","volume":"46","author":"Lubberts","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","article-title":"IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis","volume":"74","author":"Adamopoulos","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/art.10173","article-title":"Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein","volume":"46","author":"Bush","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B44","first-page":"1137","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume-title":"Lancet.","author":"McInnes","year":"2015"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","article-title":"Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study","volume":"73","author":"Genovese","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3899\/jrheum.150117","article-title":"Efficacy and safety of subcutaneous and intravenous loading dose regimens of secukinumab in patients with active rheumatoid arthritis: results from a randomized phase II study","volume":"43","author":"Tlustochowicz","year":"2016","journal-title":"J Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"19396","DOI":"10.1073\/pnas.0806855105","article-title":"Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis","volume":"105","author":"Flores-Borja","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"R335","DOI":"10.1186\/ar1192","article-title":"CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease","volume":"6","author":"Cao","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"B56","first-page":"710","article-title":"Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis","volume-title":"Rheumatology.","author":"Bonelli","year":"2016"},{"key":"B57","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s10875-011-9527-5","article-title":"CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis","volume":"31","author":"Alvarez-Quiroga","year":"2011","journal-title":"J Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","article-title":"A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination","volume":"54","author":"Klareskog","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"R159","DOI":"10.1186\/ar4342","article-title":"Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case-control study","volume":"15","author":"Arkema","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"728610","DOI":"10.1155\/2015\/728610","article-title":"The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"2015","author":"Jilani","year":"2015","journal-title":"Int J Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Rantapaa-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B63","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B64","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/annrheumdis-2015-208094","article-title":"Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism","volume":"75","author":"Wigerblad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/ard.2009.124537","article-title":"Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis","volume":"69","author":"van der Woude","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.27386","article-title":"Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte\/macrophages and stimulate tumor necrosis factor alpha production","volume":"62","author":"Lu","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B67","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.1038\/ncomms7651","article-title":"Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss","volume":"6","author":"Harre","year":"2015","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","article-title":"Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss","volume":"75","author":"Krishnamurthy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2013-203565","article-title":"Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis","volume":"74","author":"Rombouts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.semarthrit.2016.09.011","article-title":"Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis","volume":"46","author":"Wunderlich","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B72","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/ard.2005.040998","article-title":"Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation","volume":"65","author":"Alenius","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00296-014-2956-8","article-title":"Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?","volume":"34","author":"Perez-Alamino","year":"2014","journal-title":"Rheumatol Int"},{"key":"B74","first-page":"259","article-title":"Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug","volume":"26","author":"Rich","year":"1999","journal-title":"J Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.11481","article-title":"Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission","volume":"50","author":"Molenaar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1002\/art.23945","article-title":"An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis","volume":"58","author":"Brown","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B77","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/art.23653","article-title":"Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption","volume":"58","author":"Tunyogi-Csapo","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B79","first-page":"1635","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17","volume-title":"Rheumatology.","author":"Hashizume","year":"2008"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.38218","article-title":"Combination of tumor necrosis factor alpha and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo","volume":"66","author":"Yokota","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"11846","DOI":"10.1074\/jbc.M512624200","article-title":"Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression","volume":"281","author":"Yao","year":"2006","journal-title":"J Biol Chem"},{"key":"B83","first-page":"282","article-title":"IL-1 mediates TNF-induced osteoclastogenesis","volume-title":"J Clin Invest.","author":"Wei","year":"2005"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","article-title":"A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores","volume":"43","author":"Jiang","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B86","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/978-1-4419-6612-4_34","article-title":"TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling","volume":"691","author":"Findlay","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1359\/JBMR.040907","article-title":"Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6","volume":"19","author":"Holmen","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1242\/dev.01564","article-title":"Sequential roles of Hedgehog and Wnt signaling in osteoblast development","volume":"132","author":"Hu","year":"2005","journal-title":"Development"},{"key":"B89","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/ard.2010.132423","article-title":"A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis","volume":"70","author":"Finzel","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2011-201075","article-title":"Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study","volume":"72","author":"Finzel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.33504","article-title":"Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway","volume":"64","author":"Matzelle","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/art.40156","article-title":"Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial","volume":"69","author":"Solomon","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0002-9440(10)63144-6","article-title":"Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis","volume":"164","author":"Redlich","year":"2004","journal-title":"Am J Pathol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1128\/MCB.25.12.4946-4955.2005","article-title":"Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling","volume":"25","author":"Ai","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.str.2011.07.005","article-title":"Wnt antagonists bind through a short peptide to the first beta-propeller domain of LRP5\/6","volume":"19","author":"Bourhis","year":"2011","journal-title":"Structure"},{"key":"B96","doi-asserted-by":"publisher","first-page":"14700","DOI":"10.1073\/pnas.0702305104","article-title":"R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6","volume":"104","author":"Binnerts","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B97","doi-asserted-by":"publisher","first-page":"211ra158","DOI":"10.1126\/scitranslmed.3006627","article-title":"Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome","volume":"5","author":"Kedlaya","year":"2013","journal-title":"Sci Transl Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.intimp.2018.04.019","article-title":"The serum level of Dickkopf-1 in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"59","author":"Ma","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar4305","article-title":"Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study","volume":"15","author":"Marenzana","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"330ra35","DOI":"10.1126\/scitranslmed.aac4351","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"8","author":"Wehmeyer","year":"2016","journal-title":"Sci Transl Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cell.2018.07.029","article-title":"Identification of the human skeletal stem cell","volume":"175","author":"Chan","year":"2018","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13075-015-0870-4","article-title":"High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation","volume":"17","author":"Lee","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1002\/art.24888","article-title":"Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis","volume":"60","author":"Appel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s10067-017-3734-2","article-title":"In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls","volume":"36","author":"Fassio","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"9295313","DOI":"10.1155\/2017\/9295313","article-title":"Serum sclerostin levels in patients with ankylosing spondylitis and rheumatoid arthritis: a systematic review and meta-analysis","volume":"2017","author":"Shi","year":"2017","journal-title":"Biomed Res Int"},{"key":"B109","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-018-0482-7","article-title":"Coupling of bone resorption and formation by RANKL reverse signalling","volume":"561","author":"Ikebuchi","year":"2018","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:18:10Z","timestamp":1554250690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2019.00679"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00679","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"article-number":"679"}}